Summit’s Utrophin Modulation Program (January 2017)

On January 25, 2017, PPMD and Summit hosted an educational webinar on utrophin modulation, an approach for Duchenne that has the potential to treat all patients. Summit’s Jon Tinsley, Chief Scientific Officer, and Ralf Rosskamp, Chief Medical Officer, discussed:

• The basic biology of utrophin
• How Summit is working to understand and characterize the activity of utrophin modulators through biomarkers in muscle biopsies
• A brief overview of the company’s current Phase 2 clinical trial, PhaseOut DMD, which is ongoing in the US and UK